Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

10.43 -0.12 (-1.14%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 17, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,810,928
Open	10.45
Bid (Size)	10.43 (300)
Ask (Size)	11.00 (900)
Prev. Close	10.55
Today's Range	10.28 - 11.15
52wk Range	4.500 - 10.60
Shares Outstanding	30,674,855
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Today 16:28 EDT

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data ↗

Today 4:01 EDT

Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following...

Via MarketBeat

Performance

YTD	+74.1%	+74.1%
1 Month	+33.4%	+33.4%
3 Month	+56.6%	+56.6%
6 Month	+102.5%	+102.5%
1 Year	+38.1%	+38.1%

More News

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

August 13, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 11, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 04, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

June 29, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 22, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

May 27, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 13, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 12, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

May 11, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Unusual volume stocks are being observed in Tuesday's session. ↗

April 28, 2026

Via Chartmill

These stocks are moving in today's session ↗

April 27, 2026

Via Chartmill

Top stock movements in today's session. ↗

April 27, 2026

Via Chartmill

Why Sagimet Biosciences Stock Is Soaring Today ↗

April 27, 2026

Via The Motley Fool

These stocks are gapping in today's session ↗

April 27, 2026

Via Chartmill

Top movers in Monday's pre-market session ↗

April 27, 2026

Via Chartmill

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

April 27, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Provides Strategic and Corporate Updates

April 27, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

April 20, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 06, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

March 11, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

February 25, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

February 05, 2026

From Sagimet Biosciences Inc.

Via GlobeNewswire

Tuesday's session: gap up and gap down stocks ↗

February 03, 2026

Via Chartmill

Frequently Asked Questions

Is Sagimet Biosciences Inc. - Series A Common Stock publicly traded?

Yes, Sagimet Biosciences Inc. - Series A Common Stock is publicly traded.

What exchange does Sagimet Biosciences Inc. - Series A Common Stock trade on?

Sagimet Biosciences Inc. - Series A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock?

The ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock is SGMT on the Nasdaq Stock Market

What is the current price of Sagimet Biosciences Inc. - Series A Common Stock?

The current price of Sagimet Biosciences Inc. - Series A Common Stock is 10.43

When was Sagimet Biosciences Inc. - Series A Common Stock last traded?

The last trade of Sagimet Biosciences Inc. - Series A Common Stock was at 08/17/26 04:00 PM ET

What is the market capitalization of Sagimet Biosciences Inc. - Series A Common Stock?

The market capitalization of Sagimet Biosciences Inc. - Series A Common Stock is 319.94M

How many shares of Sagimet Biosciences Inc. - Series A Common Stock are outstanding?

Sagimet Biosciences Inc. - Series A Common Stock has 320M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.